Andrew Baker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Baker has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Birgit Richter
Fachbereich Mathematik der Universität Hamburg
10 shared publications Birgit Richter
7 shared publicationsJi Ho Kim
4 shared publicationsSoon Young Shin
4 shared publications- Yoongho Lim
Division of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea
4 shared publications Young Han Lee
4 shared publications
Latest Publications
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , B038
Abstract B038: Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
Directly targeting RAS is a desirable approach for treating RAS-mutated tumors because direct RAS inhibitors block all RAS effector pathways simultaneously. Recently, several groups have developed agents that directly target KRAS by covalently modifying KRASG12C. KRAS is commonly altered in adult malignancies such as lung, pancreatic, and colorectal adenocarcinoma, but is less commonly altered in pediatric cancer. However, rare pediatric tumors harboring K-, H-, or NRASG12C are observed. The efficacy of KRASG12C inhibitors in pediatric malignancies is currently unknown, and the ability of these drugs to modify H- and NRASG12C has been incompletely characterized. Here we show that the KRASG12C inhibitors AMG 510, MRTX849, and ARS-1620 slow the release of GDP from H-, N-, and KRASG12C in vitro. Using RASless MEFs, we show that the activity of AMG 510 is specific for H-, N- or KRASG12C, while MRTX849 has both G12C and RAS-independent effects on cell viability. The KRASG12C inhibitors decreased cell viability in KRAS-mutant cell lines derived from patients with the pediatric solid tumor neuroblastoma. MRTX849 was more potent than AMG 510 in neuroblastoma cell lines but was less efficacious and less G12C-specific. The KRASG12C inhibitors also decreased cell viability in an NRASG12C-mutant T-cell ALL cell line derived from an adolescent patient but only MTRX849 decreased cell viability in an HRASG12C-mutant rhabdomyosarcoma cell line. These results suggest that KRASG12C inhibitors may be a treatment option for pediatric patients with H-, N- or KRASG12C mutant solid tumors or leukemia. Future studies will be aimed at testing the efficacy of these inhibitors in xenograft models of pediatric cancer and identifying non-RAS targets of MRTX849. Citation Format: Hannah Price, Stacey Stauffer, Katie Powell, Andrew Baker, Andrew Perciaccante, Edjay Ralph Hernandez, Patience Odeniyide, Christine Pratilas, William Burgan, Lisa Jenkins, Kent L. Rossman, Marielle Yohe. Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr B038.
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , B038
Open AccessAbstract B038: Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
Directly targeting RAS is a desirable approach for treating RAS-mutated tumors because direct RAS inhibitors block all RAS effector pathways simultaneously. Recently, several groups have developed agents that directly target KRAS by covalently modifying KRASG12C. KRAS is commonly altered in adult malignancies such as lung, pancreatic, and colorectal adenocarcinoma, but is less commonly altered in pediatric cancer. However, rare pediatric tumors harboring K-, H-, or NRASG12C are observed. The efficacy of KRASG12C inhibitors in pediatric malignancies is currently unknown, and the ability of these drugs to modify H- and NRASG12C has been incompletely characterized. Here we show that the KRASG12C inhibitors AMG 510, MRTX849, and ARS-1620 slow the release of GDP from H-, N-, and KRASG12C in vitro. Using RASless MEFs, we show that the activity of AMG 510 is specific for H-, N- or KRASG12C, while MRTX849 has both G12C and RAS-independent effects on cell viability. The KRASG12C inhibitors decreased cell viability in KRAS-mutant cell lines derived from patients with the pediatric solid tumor neuroblastoma. MRTX849 was more potent than AMG 510 in neuroblastoma cell lines but was less efficacious and less G12C-specific. The KRASG12C inhibitors also decreased cell viability in an NRASG12C-mutant T-cell ALL cell line derived from an adolescent patient but only MTRX849 decreased cell viability in an HRASG12C-mutant rhabdomyosarcoma cell line. These results suggest that KRASG12C inhibitors may be a treatment option for pediatric patients with H-, N- or KRASG12C mutant solid tumors or leukemia. Future studies will be aimed at testing the efficacy of these inhibitors in xenograft models of pediatric cancer and identifying non-RAS targets of MRTX849. Citation Format: Hannah Price, Stacey Stauffer, Katie Powell, Andrew Baker, Andrew Perciaccante, Edjay Ralph Hernandez, Patience Odeniyide, Christine Pratilas, William Burgan, Lisa Jenkins, Kent L. Rossman, Marielle Yohe. Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr B038.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Transcription Factor Egr-1 Is Essential for Maximal Matrix Metalloproteinase-9 Transcription by Tumor Necrosis Factor α
Matrix metalloproteinase-9 (MMP-9) is involved in a wide range of normal and pathologic conditions, including inflammation, tissue repair, tumor invasion, and metastasis. Tumor necrosis factor α (TNFα) is a major proinflammatory cytokine that plays crucial roles in tumor progression, including tumor invasion and metastasis in the tumor microenvironment. Egr-1 is a member of the zinc-finger transcription factor family induced by diverse stimuli, including TNFα. However, the role of Egr-1 in MMP-9 expression was previously unknown. This study shows that Egr-1 directly binds to the MMP-9 promoter and plays an essential role for TNFα induction of MMP-9 transcription. Furthermore, Egr-1 together with NF-κB can synergistically activate both basal and TNFα-induced MMP-9 promoter activities in the presence of p300. We found that Egr-1 mediates extracellular signal–regulated kinase and c-jun NH2-terminal kinase mitogen-activated protein kinase–dependent MMP-9 transcription on TNFα stimulation. The requirement for Egr-1 in MMP-9 expression is further supported by the fact that HeLa cells expressing Egr-1 siRNA and Egr-1–null mouse embryonic fibroblasts were refractory to TNFα-induced MMP-9 expression. This report establishes that Egr-1 is essential for MMP-9 transcription in response to TNFα within the tumor microenvironment. Mol Cancer Res; 8(4); 507–19. ©2010 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transcription Factor Egr-1 Is Essential for Maximal Matrix Metalloproteinase-9 Transcription by Tumor Necrosis Factor α
Matrix metalloproteinase-9 (MMP-9) is involved in a wide range of normal and pathologic conditions, including inflammation, tissue repair, tumor invasion, and metastasis. Tumor necrosis factor α (TNFα) is a major proinflammatory cytokine that plays crucial roles in tumor progression, including tumor invasion and metastasis in the tumor microenvironment. Egr-1 is a member of the zinc-finger transcription factor family induced by diverse stimuli, including TNFα. However, the role of Egr-1 in MMP-9 expression was previously unknown. This study shows that Egr-1 directly binds to the MMP-9 promoter and plays an essential role for TNFα induction of MMP-9 transcription. Furthermore, Egr-1 together with NF-κB can synergistically activate both basal and TNFα-induced MMP-9 promoter activities in the presence of p300. We found that Egr-1 mediates extracellular signal–regulated kinase and c-jun NH2-terminal kinase mitogen-activated protein kinase–dependent MMP-9 transcription on TNFα stimulation. The requirement for Egr-1 in MMP-9 expression is further supported by the fact that HeLa cells expressing Egr-1 siRNA and Egr-1–null mouse embryonic fibroblasts were refractory to TNFα-induced MMP-9 expression. This report establishes that Egr-1 is essential for MMP-9 transcription in response to TNFα within the tumor microenvironment. Mol Cancer Res; 8(4); 507–19. ©2010 AACR.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Transcription Factor Egr-1 Is Essential for Maximal Matrix Metalloproteinase-9 Transcription by Tumor Necrosis Factor α
Matrix metalloproteinase-9 (MMP-9) is involved in a wide range of normal and pathologic conditions, including inflammation, tissue repair, tumor invasion, and metastasis. Tumor necrosis factor α (TNFα) is a major proinflammatory cytokine that plays crucial roles in tumor progression, including tumor invasion and metastasis in the tumor microenvironment. Egr-1 is a member of the zinc-finger transcription factor family induced by diverse stimuli, including TNFα. However, the role of Egr-1 in MMP-9 expression was previously unknown. This study shows that Egr-1 directly binds to the MMP-9 promoter and plays an essential role for TNFα induction of MMP-9 transcription. Furthermore, Egr-1 together with NF-κB can synergistically activate both basal and TNFα-induced MMP-9 promoter activities in the presence of p300. We found that Egr-1 mediates extracellular signal–regulated kinase and c-jun NH2-terminal kinase mitogen-activated protein kinase–dependent MMP-9 transcription on TNFα stimulation. The requirement for Egr-1 in MMP-9 expression is further supported by the fact that HeLa cells expressing Egr-1 siRNA and Egr-1–null mouse embryonic fibroblasts were refractory to TNFα-induced MMP-9 expression. This report establishes that Egr-1 is essential for MMP-9 transcription in response to TNFα within the tumor microenvironment. Mol Cancer Res; 8(4); 507–19. ©2010 AACR.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transcription Factor Egr-1 Is Essential for Maximal Matrix Metalloproteinase-9 Transcription by Tumor Necrosis Factor α
Matrix metalloproteinase-9 (MMP-9) is involved in a wide range of normal and pathologic conditions, including inflammation, tissue repair, tumor invasion, and metastasis. Tumor necrosis factor α (TNFα) is a major proinflammatory cytokine that plays crucial roles in tumor progression, including tumor invasion and metastasis in the tumor microenvironment. Egr-1 is a member of the zinc-finger transcription factor family induced by diverse stimuli, including TNFα. However, the role of Egr-1 in MMP-9 expression was previously unknown. This study shows that Egr-1 directly binds to the MMP-9 promoter and plays an essential role for TNFα induction of MMP-9 transcription. Furthermore, Egr-1 together with NF-κB can synergistically activate both basal and TNFα-induced MMP-9 promoter activities in the presence of p300. We found that Egr-1 mediates extracellular signal–regulated kinase and c-jun NH2-terminal kinase mitogen-activated protein kinase–dependent MMP-9 transcription on TNFα stimulation. The requirement for Egr-1 in MMP-9 expression is further supported by the fact that HeLa cells expressing Egr-1 siRNA and Egr-1–null mouse embryonic fibroblasts were refractory to TNFα-induced MMP-9 expression. This report establishes that Egr-1 is essential for MMP-9 transcription in response to TNFα within the tumor microenvironment. Mol Cancer Res; 8(4); 507–19. ©2010 AACR.
- Open Access
Homotopy theory of modules over a commutative $S$-algebra: some tools and examples
Modern categories of spectra such as that of Elmendorf et al equipped with strictly symmetric monoidal smash products allows the introduction of symmetric monoids providing a new way to study highly coherent commutative ring spectra. These have categories of modules which are generalisations of the classical categories of spectra that correspond to modules over the sphere spectrum; passing to their derived or homotopy categories leads to new contexts in which homotopy theory can be explored. In this paper we describe some of the tools available for studying these `brave new homotopy theories' and demonstrate them by considering modules over the $K$-theory spectrum, closely related to Mahowald's theory of $bo$-resolutions. In a planned sequel we will apply these techniques to the much less familiar context of modules over the $2$-local connective spectrum of topological modular forms.
Open AccessHomotopy theory of modules over a commutative $S$-algebra: some tools and examples
Modern categories of spectra such as that of Elmendorf et al equipped with strictly symmetric monoidal smash products allows the introduction of symmetric monoids providing a new way to study highly coherent commutative ring spectra. These have categories of modules which are generalisations of the classical categories of spectra that correspond to modules over the sphere spectrum; passing to their derived or homotopy categories leads to new contexts in which homotopy theory can be explored. In this paper we describe some of the tools available for studying these `brave new homotopy theories' and demonstrate them by considering modules over the $K$-theory spectrum, closely related to Mahowald's theory of $bo$-resolutions. In a planned sequel we will apply these techniques to the much less familiar context of modules over the $2$-local connective spectrum of topological modular forms.
- Open Access
Power operations in $K$-theory completed at a prime
We describe the action of power operations on the $p$-completed cooperation algebras $K^\vee_0 K = K_0(K)\sphat_p$ for $K$-theory at a prime~$p$, and $K^\vee_0 KO = K_0(KO)\sphat_2$.Open AccessPower operations in $K$-theory completed at a prime
We describe the action of power operations on the $p$-completed cooperation algebras $K^\vee_0 K = K_0(K)\sphat_p$ for $K$-theory at a prime~$p$, and $K^\vee_0 KO = K_0(KO)\sphat_2$. - 20 July 2020
- Published by Mathematical Sciences Publishers in Algebraic & Geometric Topology
- Vol. 20 (4) , 2129-2143
The realizability of some finite-length modules over the Steenrod algebra by spaces
- 20 July 2020
- Published by Mathematical Sciences Publishers in Algebraic & Geometric Topology
- Vol. 20 (4) , 2129-2143
The realizability of some finite-length modules over the Steenrod algebra by spaces
- Open Access
The realizability of some finite-length modules over the Steenrod algebra by spaces
The Joker is an important finite cyclic module over the mod-$2$ Steenrod algebra $\mathcal A$. We show that the Joker, its first two iterated Steenrod doubles, and their linear duals are realizable by spaces of as low a dimension as the instability condition of modules over the Steenrod algebra permits. This continues and concludes prior work by the first author and yields a complete characterization of which versions of Jokers are realizable by spaces or spectra and which are not. The constructions involve sporadic phenomena in homotopy theory ($2$-compact groups, topological modular forms) and may be of independent interest.Open AccessThe realizability of some finite-length modules over the Steenrod algebra by spaces
The Joker is an important finite cyclic module over the mod-$2$ Steenrod algebra $\mathcal A$. We show that the Joker, its first two iterated Steenrod doubles, and their linear duals are realizable by spaces of as low a dimension as the instability condition of modules over the Steenrod algebra permits. This continues and concludes prior work by the first author and yields a complete characterization of which versions of Jokers are realizable by spaces or spectra and which are not. The constructions involve sporadic phenomena in homotopy theory ($2$-compact groups, topological modular forms) and may be of independent interest. - Open Access
- 29 July 2019
- Published by Radiopaedia Australia Pty Ltd
Midshaft radius and ulnar fractures
The degree of angulation in forearm fractures is a key determinant for management. In this case, the angulation was greater than acceptable, and could not be maintained in an adequate position following closed reduction. Hence, ORIF with Titaniu...
- 29 July 2019
- Published by Radiopaedia Australia Pty Ltd
Open AccessMidshaft radius and ulnar fractures
The degree of angulation in forearm fractures is a key determinant for management. In this case, the angulation was greater than acceptable, and could not be maintained in an adequate position following closed reduction. Hence, ORIF with Titaniu...